Decitabine (5-Aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations

Leukemia

Volumn 11, Issue SUPPL. 1, 1997, Pages

  Schwartsmann, G ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

5 Aza 2 deoxycytidine; Acute myeloid leukemia; DAC; Decitabine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALOPECIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0030990163     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Keating A, Crump M. Acute leukemia in adults. Curr Opin Hematol 1995;2: 247-254.
2. Gale RP, Foon KA. Therapy of acute myelogenous leukemia. Semin Hematol 1987; 24: 40-54.